$1.09
3.54%
Nasdaq, Apr 25, 10:00 pm CET
ISIN
US30234E1047
Symbol
EYEN
Sector
Industry

Eyenovia, Inc. Stock price

$1.09
-0.24 18.05% 1M
-42.05 97.47% 6M
-10.59 90.67% YTD
-55.81 98.08% 1Y
-194.11 99.44% 3Y
-248.51 99.56% 5Y
-792.51 99.86% 10Y
Nasdaq, Closing price Fri, Apr 25 2025
-0.04 3.54%
ISIN
US30234E1047
Symbol
EYEN
Sector
Industry

Key metrics

Market capitalization $3.09m
Enterprise Value $12.22m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 203.67
P/S ratio (TTM) P/S ratio 51.50
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 1,414.02%
Revenue (TTM) Revenue $60.00k
EBIT (operating result TTM) EBIT $-32.67m
Free Cash Flow (TTM) Free Cash Flow $-30.28m
Cash position $2.12m
EPS (TTM) EPS $-61.97
P/S forward 0.81
EV/Sales forward 3.22
Short interest 2.95%
Show more

Is Eyenovia, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

Eyenovia, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Eyenovia, Inc.:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Eyenovia, Inc.:

Hold
100%

Financial data from Eyenovia, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.06 0.06
-
100%
- Direct Costs 4.86 4.86
354% 354%
8,100%
-4.80 -4.80
353% 353%
-8,000%
- Selling and Administrative Expenses 13 13
23% 23%
22,333%
- Research and Development Expense 13 13
8% 8%
22,217%
-32 -32
30% 30%
-52,567%
- Depreciation and Amortization 1.13 1.13
7% 7%
1,883%
EBIT (Operating Income) EBIT -33 -33
29% 29%
-54,443%
Net Profit -50 -50
83% 83%
-83,033%

In millions USD.

Don't miss a Thing! We will send you all news about Eyenovia, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eyenovia, Inc. Stock News

Neutral
GlobeNewsWire
18 days ago
On track for regulatory submission seeking marketing approval of the Optejet UFD in Q4 2025 On track for regulatory submission seeking marketing approval of the Optejet UFD in Q4 2025
Neutral
GlobeNewsWire
about one month ago
Combination, if successful, would create a new publicly-listed eye care company combining Betaliq's EyeSol ® water-free drug delivery technology for glaucoma with Eyenovia's Optejet ® device platform
Neutral
GlobeNewsWire
2 months ago
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announced that it has been informed by staff of The Nasdaq Stock Market LLC that the Company has regained compliance with all Nasdaq Capital Market continued listing requirements, inc...
More Eyenovia, Inc. News

Company Profile

Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.

Head office United States
CEO Michael Rowe
Employees 14
Founded 2014
Website www.eyenovia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today